Nanjing Vazyme Biotech Co., Ltd.
688105.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.75B
Close$
Compare to Similar Companies
| P/E Ratio | Dividends | Return on Equity | Price-to-Sales | Debt-to-Equity | ||
|---|---|---|---|---|---|---|
| Nanjing Vazyme Biotech Co., Ltd. | 5111285337090360000 | 1.88% | 0% | 3.8 | 0.2 | |
$6.43
75.8% downside
Current Fair Value
75.8% downsideOvervalued by 75.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.75 Billion |
|---|---|
| Enterprise Value | $14.00 Billion |
| Dividend Yield | $0.50 (1.88%) |
| Earnings per Share | $-0.04 |
| Beta | 0.68 |
| Outstanding Shares | 187,762,059 |
Return
| Return on Equity | -0.25% |
|---|---|
| Return on Assets | -0.20% |
| Return on Invested Capital | -1.41% |
Valuation & Multiples
| P/E Ratio | 5111285337090360000 |
|---|---|
| PEG | 1120756547753937900 |
| Price to Sales | 3.8 |
| Price to Book Ratio | 1.4 |
| Enterprise Value to Revenue | 9.51 |
| Enterprise Value to EBIT | -262.21 |
| Enterprise Value to Net Income | -1532 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$975.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nanjing Vazyme Biotech Co., Ltd.
3,002 employees
CEO: Lin Cao Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodi...